![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Fibrosarcoma - 88 Studies Found
Recruiting |
: To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors :
: Drug: nab-paclitaxel nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle |
Recruiting |
: Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery :
|
Active, not recruiting |
: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma :
|
Completed |
: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas :
|
Recruiting |
: Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma :
|
Completed |
: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma :
|
Completed |
: Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma : Sarcoma : 2004-06-10 :
|
Recruiting |
: Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors :
: 2015-12-10 : Drug: LOXO-101 (larotrectinib) Capsules / Liquid Administration |
Terminated |
: Phase II Pazopanib Study in Advanced Dermatofibrosarcomas : Dermatofibrosarcomas of DARIER FERRAND(DFSP) : 2010-01-28 : Drug: Pazopanib Administration of pazopanib per os 800mg/ qd during 6 months until stable response accor |